Precigen (NASDAQ: PGEN) CEO nets 321,100 shares from RSUs

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

PRECIGEN, INC. President and CEO Helen Sabzevari received a grant of 321,100 restricted stock units on March 18, 2026, each representing one share of common stock. The RSUs vested immediately on the grant date as part of her equity compensation.

She then exercised these 321,100 RSUs at $0.00 per unit, converting them into 321,100 shares of common stock. Following the transactions, she directly holds 3,638,122 shares of Precigen common stock. These are compensation-related acquisitions, not open-market purchases.

Insider Trade Summary

321,100 shares exercised/converted

Mixed 3 txns

Insider Sabzevari Helen

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	321,100	$0.00	--
Exercise	Restricted Stock Units	321,100	$0.00	--
Exercise	Common Stock	321,100	$0.00	--

Holdings After Transaction: Restricted Stock Units — 321,100 shares (Direct); Common Stock — 3,638,122 shares (Direct)

Footnotes (1)

Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock. The RSUs vested immediately upon the grant date.

Form 4 Insider Transactions: What Each Field Means →

03/20/2026 - 07:27 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sabzevari Helen

(Last)

(First)

(Middle)

20374 SENECA MEADOWS PARKWAY

(Street)

GERMANTOWN

MARYLAND

20876

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PRECIGEN, INC. [ PGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/18/2026		M		321,100	A	⁽¹⁾	3,638,122	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	03/18/2026		A		321,100		⁽²⁾	⁽²⁾	Common Stock	321,100	$0	321,100	D
Restricted Stock Units	⁽¹⁾	03/18/2026		M			321,100	⁽²⁾	⁽²⁾	Common Stock	321,100	$0	0	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock.

2. The RSUs vested immediately upon the grant date.

	/s/ Helen Sabzevari, by Donald P. Lehr, as attorney-in-fact	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Precigen (PGEN) CEO Helen Sabzevari report in this Form 4?

Helen Sabzevari reported a grant and immediate vesting of 321,100 restricted stock units, then exercised them into common stock. These awards are part of her equity compensation and do not reflect open-market buying or selling activity.

How many Precigen (PGEN) shares did the CEO acquire from RSUs?

The CEO acquired 321,100 shares of Precigen common stock by exercising 321,100 restricted stock units. Each RSU converted into one share at a price of zero, consistent with standard stock-based compensation grants for senior executives.

Did the Precigen (PGEN) CEO buy or sell shares on the open market?

No open-market buy or sell occurred. The filing shows only equity compensation events: a grant of restricted stock units that vested immediately and a corresponding exercise into common shares, all at a stated price of zero per unit.

What are restricted stock units (RSUs) in the Precigen (PGEN) CEO’s filing?

In this filing, each restricted stock unit represents a contingent right to receive one share of Precigen common stock. The RSUs vested immediately on the grant date, then were exercised, creating an equivalent number of common shares for the CEO.

How many Precigen (PGEN) shares does the CEO hold after these transactions?

After these transactions, the CEO directly holds 3,638,122 shares of Precigen common stock. This total reflects the addition of 321,100 shares acquired through the immediate vesting and exercise of restricted stock units reported in this Form 4.

Were any derivative securities left outstanding after the Precigen (PGEN) RSU exercise?

The summary data shows no remaining derivative securities after this RSU exercise. The reported restricted stock units were fully exercised into common shares, and no additional RSU or option positions are listed in the remaining derivative holdings section.